Serum Institute of India will perform an observer-blind, randomised controlled study enrolling at least 1,600 participants to determine the safety and immunogenicity of ‘Covishield’ for coronavirus treatment.
source https://www.hindustantimes.com/india-news/serum-institute-asked-to-revise-protocol-for-covid-19-vaccine-clinical-trial/story-etC5FRuLLZitcGT0TgyuTI.html
No comments:
Post a Comment